Introduction: Pathophysiological interaction between the heart and kidneys represents the basis for clinical entities called cardiorenal syndromes. The purpose of the study was to assess the relations between acute and chronic cardiorenal syndromes and biomarkers [advanced oxidation protein products, brain natriuretic peptide, malondialdehyde, xanthine oxidoreductase (XOD), xanthine oxidase, xanthine dehydrogenase, interleukin 8, cystatin C, plasminogen activator inhibitor-1, high-sensitive troponin T, C-reactive protein and glomerular filtration rate, measured by the Modification of Diet in Renal Disease (MDRD) formula], to hypothesize biomarkers that might provide a prompt identification of acute or chronic cardiorenal syndromes, and to distinguish acute versus chronic types of these syndromes. Methods: A total of 114 participants were enrolled in this study, i.e. 79 patients divided into subgroups of acute and chronic cardiorenal syndromes and 35 volunteers. Results: Nonadjusted odds ratio (OR) showed that there was a significant risk for acute cardiorenal syndrome with increased XOD activity (p = 0.037), elevated cystatin C concentration (p = 0.038) and MDRD (p = 0.028). Multivariable adjusted OR, on the other hand, revealed that only glomerular filtration rate measured by the MDRD formula had a significance for acute cardiorenal syndrome (p = 0.046). Nonadjusted OR showed a significant risk for chronic cardiorenal syndrome only in elderly (p = 0.002). Multivariable adjusted OR exhibited that age was the only risk factor for chronic cardiorenal syndrome (p = 0.012). Conclusion: Cystatin C, glomerular filtration rate measured by the MDRD equation and XOD were independent risk factors for acute cardiorenal syndrome, while age remained an independent risk factor for chronic cardiorenal syndrome. When comparing ORs of evaluated parameters, the highest significance for acute cardiorenal syndrome was plasma concentration of cystatin C.

Keywords:
Cardiorenal syndromes, Modification of Diet in Renal Disease formula, Cystatin C, Xanthine oxidoreductase
1.
Ronco C: Cardiorenal and renocardiac syndromes: clinical disorders in search of a systematic definition. Int J Artif Organs 2008;31:1-2.
2.
Liang KV, Williams AW, Greene EL, Redfield MM: Acute decompensated heart failure and the cardio-renal syndrome. Crit Care Med 2008;36(1 suppl):75-88.
3.
Taglieri N, Koenig W, Kaski JC: Cystatin C and cardiovascular risk. Clin Chem 2009;55:1932-1943.
4.
Grubb A, Bjork J, Lindstrom V, Sterner G, Bondesson P, Nyman U: A cystatin C-based formula without anthropometric variables estimates glomerular filtration rate better than creatinine clearance using the Cockcroft-Gault formula. Scand J Clin Lab Invest 2005;65:153-162.
5.
Abrahamson M, Dalboge H, Olafsson I, Carlsen S, Grubb A: Efficient production of native, biologically active human cystatin C by Escherichia coli. FEBS Lett 1988;236:14-18.
6.
Berry CE, Hare JM: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 2004;555:589-606.
7.
Kohler HP, Grant P: Plasminogen activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000;342:1792-1801.
8.
Clerico A: Pathophysiological and clinical relevance of circulating levels of cardiac natriuretic hormones: is their assay merely a marker of cardiac disease? Clin Chem Lab Med 2002;40:752-760.
9.
Sakata Y, Yamamoto K, Masuyama T, Mano T, Nishikawa N, Kuzuya T, Miwa T, Hori M: Ventricular production of natriuretic peptides and ventricular structural remodelling in hypertensive heart failure. J Hypertens 2001;19:1905-1509.
10.
McCullough PA, Kellum JA, Mehta RL, Murray PT, Ronco C: ADQI consensus on AKI biomarkers and cardiorenal syndromes. Contrib Nephrol 2013;182:82-98.
11.
Witko-Sarsat V, Gausson V, Descamps-Latscha B: Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003;84:11-14.
12.
Andreeva IL, Kozemjakin AL, Kishkun AA: Modification of the method of measurement of lipid peroxides in test with thiobarbituric acid (in Russian). Lab Delo 1988;11:41-43.
13.
Kizaki H, Sakurada T: Simple micro-assay methods for enzymes of purine metabolism. J Lab Clin Med 1977;89:1135-1144.
14.
Spiekermann S, Landmesser U, Dikalov S, Bredt M, Gamez G, Tatge H, Reepschläger N, Hornig B, Drexler H, Harrison DG: Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2003;107:1383-1389.
16.
Moran A, Katz R, Smith NL, Fried LF, Sarnak MJ, Seliger SL, Psaty B, Siscovick DS, Gottdiener JS, Shlipak MG: Cystatin C concentration as a predictor of systolic and diastolic heart failure. J Card Fail 2008;14:19-26.
17.
Carrasco-Sánchez FJ, Galisteo-Almeda L, Páez-Rubio I, Martínez-Marcos FJ, Camacho-Vázquez C, Ruiz-Frutos C, Pujol-De La Llave E: Prognostic value of cystatin C on admission in heart failure with preserved ejection fraction. J Card Fail 2011;17:31-38.
18.
Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, et al: Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
19.
Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, et al: Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 2005;142:497-505.
20.
Lassus JP, Nieminen MS, Peuhkurinen K, Pulkki K, Siirilä-Waris K, Sund R, Harjola VP: Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur Heart J 2010;31:2791-2798.
21.
Jerums G, Premaratne E, Panagiotopoulos S, et al: New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008;82(suppl 1):30-37.
22.
Damman K, Voors AA, Navis SG, van Veldhuisen DJ, Hillege HL: Current and novel renal biomarkers in heart failure. Heart Fail Rev 2012;17:241-250.
23.
Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE: Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-1421.
24.
Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, et al: Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 2009;75:652-660.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.